BioCentury | Dec 21, 2019
Politics, Policy & Law

U.S. drug industry hopes China deal ends stealth attack on IP

...2021 and May 2025. That didn’t prevent Chinese regulators from greenlighting a generic saxagliptin from Jiangsu Aosaikang Pharmaceutical Co. Ltd....
BioCentury | Apr 18, 2011
Company News

LCT, Otsuka Pharmaceutical deal

...month, Living Cell said it was in negotiations to enter a research collaboration which proposes Jiangsu Aosaikang Pharmaceutical Co. Ltd....
BioCentury | Mar 21, 2011
Company News

Jiangsu Aosaikang Pharmaceutical Co. Ltd., LCT deal

...exchange for 14.3 million Living Cell shares, which represents a 4.7% stake in the company. Jiangsu Aosaikang Pharmaceutical Co. Ltd....
BioCentury | Mar 21, 2011
Financial News

LCT completes private placement

...A$1.7 million (US$1.7 million) Shares: 14.3 million Price: A$0.12 Shares after offering: 304.7 million Investors: Jiangsu Aosaikang Pharmaceutical Co. Ltd. WIR...
BioCentury | Jun 9, 2008
Company News

Access Pharmaceuticals, Jiangsu Aosaikang Pharmaceutical Co. Ltd. deal

...and ovarian cancer are planned to begin this year. Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Jiangsu Aosaikang Pharmaceutical Co. Ltd....
Items per page:
1 - 5 of 5
BioCentury | Dec 21, 2019
Politics, Policy & Law

U.S. drug industry hopes China deal ends stealth attack on IP

...2021 and May 2025. That didn’t prevent Chinese regulators from greenlighting a generic saxagliptin from Jiangsu Aosaikang Pharmaceutical Co. Ltd....
BioCentury | Apr 18, 2011
Company News

LCT, Otsuka Pharmaceutical deal

...month, Living Cell said it was in negotiations to enter a research collaboration which proposes Jiangsu Aosaikang Pharmaceutical Co. Ltd....
BioCentury | Mar 21, 2011
Company News

Jiangsu Aosaikang Pharmaceutical Co. Ltd., LCT deal

...exchange for 14.3 million Living Cell shares, which represents a 4.7% stake in the company. Jiangsu Aosaikang Pharmaceutical Co. Ltd....
BioCentury | Mar 21, 2011
Financial News

LCT completes private placement

...A$1.7 million (US$1.7 million) Shares: 14.3 million Price: A$0.12 Shares after offering: 304.7 million Investors: Jiangsu Aosaikang Pharmaceutical Co. Ltd. WIR...
BioCentury | Jun 9, 2008
Company News

Access Pharmaceuticals, Jiangsu Aosaikang Pharmaceutical Co. Ltd. deal

...and ovarian cancer are planned to begin this year. Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Jiangsu Aosaikang Pharmaceutical Co. Ltd....
Items per page:
1 - 5 of 5